A practical reference on Research material: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-05. Anything still debated is marked as such rather than presented as settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
== Molecular weight distribution in linear polymerization == The product of a polymerization is a mixture of polymer molecules of different molecular weights. For theoretical and practical reasons, it is of interest to discuss the distribution of molecular weights in a polymerization. The molecular weight distribution (MWD) had been derived by Flory by a statistical approach based on the concept of equal reactivity of functional groups.
Korolev's conversion of his surplus Vostok capsules to the Voskhod spacecraft allowed the Soviet space program to beat the Gemini program in achieving the first spaceflight with a multi-person crew, and the first "spacewalk". Gemini took a year longer than planned to make its first flight, so Voskhod 1 became the first spaceflight with a three-person crew on October 12, 1964. The USSR touted another "technological achievement" during this mission: it was the first space flight during which cosmonauts performed in a shirt-sleeve-environment. However, flying without spacesuits was not due to safety improvements in the Soviet spacecraft's environmental systems; rather this was because the craft's limited cabin space did not allow for spacesuits. Flying without spacesuits exposed the cosmonauts to significant risk in the event of potentially fatal cabin depressurization. This was not repeated until the US Apollo Command Module flew in 1968; the command module cabin was designed to transport three astronauts in a low pressure, pure oxygen shirt-sleeve environment while in space. On March 18, 1965, about a week before the first piloted Project Gemini space flight, the USSR launched the two-cosmonaut Voskhod 2 mission with Pavel Belyayev and Alexei Leonov. Voskhod 2's design modifications included the addition of an inflatable airlock to allow for extravehicular activity (EVA), also known as a spacewalk, while keeping the cabin pressurized so that the capsule's electronics would not overheat. Leonov performed the first-ever EVA as part of the mission.
=== Ammonia solutions === The alkali metals dissolve slowly in liquid ammonia, forming ammoniacal solutions of solvated metal cation M+ and solvated electron e−, which react to form hydrogen gas and the alkali metal amide (MNH2, where M represents an alkali metal): this was first noted by Humphry Davy in 1809 and rediscovered by W. Weyl in 1864. The process may be speeded up by a catalyst. Similar solutions are formed by the heavy divalent alkaline earth metals calcium, strontium, barium, as well as the divalent lanthanides, europium and ytterbium. The amide salt is quite insoluble and readily precipitates out of solution, leaving intensely coloured ammonia solutions of the alkali metals. In 1907, Charles A. Kraus identified the colour as being due to the presence of solvated electrons, which contribute to the high electrical conductivity of these solutions. At low concentrations (below 3 M), the solution is dark blue and has ten times the conductivity of aqueous sodium chloride; at higher concentrations (above 3 M), the solution is copper-coloured and has approximately the conductivity of liquid metals like mercury. In addition to the alkali metal amide salt and solvated electrons, such ammonia solutions also contain the alkali metal cation (M+), the neutral alkali metal atom (M), diatomic alkali metal molecules (M2) and alkali metal anions (M−). These are unstable and eventually become the more thermodynamically stable alkali metal amide and hydrogen gas. Solvated electrons are powerful reducing agents and are often used in chemical synthesis.
== Early business career == Bello entered the Amos Tuck School at Dartmouth College, graduating with an MBA in 1974. While at Tuck he was named an Edward Tuck Scholar. After Tuck, his first business position was in brand management at General Foods, where he worked on Sanka and Maxwell House coffee brands. After an interim experience in athletic footwear as product director for Keds Brand footwear, he moved on to a strategic planning and marketing functions in the Pepsi Cola Division of PepsiCo where he worked on Mountain Dew and the Pepsi Challenge.
Sources: en.wikipedia.org
== Further reading == Whitman, William B., et al., eds. Bergey's manual of systematic bacteriology. Vol. 2. Springer, 2012. Sagarzazu, Noelia Isabel, et al. "Optimization of denaturing high performance liquid chromatography technique for rapid detection and identification of acetic acid bacteria of interest in vinegar production." Acetic Acid Bacteria 2.1s (2013): e5. Solieri, Lisa, and Paolo Giudici. Vinegars of the World. Springer Milan, 2009.
conformational change A change in the spatial conformation or physical shape of a molecule or macromolecule such as a protein or nucleic acid, rarely spontaneously but more commonly as a result of some alteration in the molecule's chemical environment (e.g. temperature, pH, salt concentration, etc.) or an interaction with another molecule. Changes in the tertiary structures of proteins can affect whether or how strongly they bind ligands or substrates; inducing these changes is a common means (both naturally and artificially) of activating, inactivating, or otherwise controlling the function of many enzymes and receptor proteins.
=== Oceania === Since the end of Australia’s Whitlam government, the Australian Labour Party (ALP) has moved towards centrist policies and Third Way ideals which are supported by the ALP's Right Faction members while the supporters of democratic socialism and social democracy lie within the ALP's Left Faction. There has been an increase in interest for socialism in recent years, especially among young adults. Interest is strongest in Victoria, where the Victorian Socialists party was founded. 2017-23 Prime Minister Jacinda Ardern of the democratic socialist New Zealand Labour Party, who has called capitalism a "blatant failure" due to the extent of homelessness in New Zealand, has been described and identified herself as democratic socialist. In Melanesia, Melanesian socialism was inspired by African socialism and developed in the 1980s. It aims to achieve full independence from Britain and France in Melanesian territories and creation of a Melanesian federal union. It is very popular with the New Caledonia independence movement.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.